Neurocrine Biosciences
在场
是其中之一......
Neurocrine Biosciences 是一家在股票代码 NBIX (US) 下上市的公司。
Neurocrine Biosciences 在 2 个国家有直接业务。
他们在：
高管
查看带有其 27 名主要高管的组织结构图
Neurocrine Biosciences 搜索最多的简介
高管在Neurocrine Biosciences变化
- Kevin Gorman, President, Chief Executive Officer and Director, 将于 202410月11 退休 (新闻发布的2024五月29号).
- Kyle Gano 曾任 Chief Business Development and Strategy Officer, 将于 202410月11 升职为 Chief Executive Officer (新闻发布的2024五月29号).
创建提醒
跟踪 Neurocrine Biosciences 的高管变动
生物技术
Neurocrine Biosciences 拥有 2,333 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Visus Therapeutics and Tenpoint Therapeutics have merged (公布2024十二月27号)..
- Deerfield has announced the acquisition of Singular Genomics (公布2024十二月24号).
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Neurocrine Biosciences 的最新新闻稿
- Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia | Neurocrine Biosciences
- Neurocrine Biosciences to Participate at Investor Conferences in December | Neurocrine Biosciences
- Neurocrine Biosciences to Participate at Investor Conferences in November | Neurocrine Biosciences
- Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules | Neurocrine Biosciences
- Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules | Neurocrine Biosciences
- Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia | Neurocrine Biosciences
- Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance | Neurocrine Biosciences
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results | Neurocrine Biosciences
- News & Media | neurocrine.com
- Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use | Neurocrine Biosciences
- View more press releases Close
通过电子邮件
